close

A wake-up call for HTA bodies and payers on assessing and valuing person-centered therapeutic innovations

Following publication of today’s IQVIA Report Assessing Person-Centered Therapeutic Innovations, EFPIA is calling for the inclusion of patient experience and patient preferences in Health Technology Assessment (HTA) evaluation and pricing and reimbursement decisions. Person-centered therapeutic innovations can have a significant and tangible impact on patients’ quality of life, improve adherence and as a consequence improve outcomes. Yet the report, indicates that many HTA bodies and payers do not consider person-centered therapeutic innovations meaningfully in their evaluation of new treatments.

Jean-Christophe Tellier, EFPIA President said. “We believe that the inclusion of the improvement of patient experience and patient preferences in HTA evaluation and pricing and reimbursement decisions is necessary. Person-centered therapeutic innovations can have a significant and tangible impact on patients’ quality of life, improve adherence and as a consequence improve outcomes.”

The IQVIA report, commissioned by EFPIA, outlined the significant difference between how payers and end users (patients & clinicians) perceive the value of person-centered therapeutic innovations. The report found that many payers and HTA bodies often overlook the added value of such innovations. In fact, many HTA bodies do not consider patient experience benefits in their own right, favoring a more singular focus on clinical outcomes.
David Haerry from the European Aids Treatment Group (EATG) has welcomed the report and called it a wake-up call: “HTA processes stand today where regulators found themselves twenty years ago - isolated from natural stakeholders and partners who have to cope with the consequences of their decision making. This report should be a wake-up call.”

The white paper can be accessed here.
/